Abstract: Familial Mediterranean fever (FMF) is the most frequent hereditary inflammatory disease characterized by self-limited recurrent attacks of fever and serositis. The aim of the current study is to determine the frequency of the mutations in 365 suspected FMF patients and to reveal whether there is a correlation between genotype and phenotype of these patients. All patients were clinically examined according to Tell-Hashomer FMF criteria and were screened genetically in terms of common 12 Mediterranean fever gene (MEFV) mutations. Various point mutations were detected in 270 (74%) patients. The most frequent mutation was M694V (26.85% of the alleles) and was followed by E148Q (15.55%), M680I (G/C) (9.62%) and V726A (7.96%). Patients who bear M694V homozygous mutation had most severe disease phenotype and high risk for amyloidosis (P = 0.04). Our results indicate that Sivas population has a wide range of heterozygous mutated carriers of MEFV gene and there is a high frequency of E148Q allele when compared to the other Mediterranean groups.
Introduction
Familial Mediterranean fever (FMF) is an autosomal recessive inherited inflammatory disease which primarily affects patients in the Mediterranean Basin populations, especially Arabs, Jews, Armenians and Turks (Sohar et al. 1967; Livneh et al. 1997; Odabas et al. 2002) . FMF is also reported in other countries of the Mediterranean, including Cyprus, Italy and Spain (Deltas et al. 2002; La Regina et al. 2003; Aldea et al. 2004) . It is characterized by recurrent, self-limited attacks of fever accompanied by peritonitis, arthritis or pleuritis and insidious development of systemic amyloidosis (Sohar et al. 1967; Ben-Chetrit & Levy 1998) . The most severe complication of the disease is progressive systemic amyloidosis that may lead to renal failure and severe complication of chronic destructive arthritis resulting in permanent organic damage to the involved joints (Zemer et al. 1991) . Some other FMF disease complications are very common in Turkish populations.
From the time of the discovery in 1997 of the MEditerranean FeVer gene (MEFV) responsible for FMF on the short arm of chromosome 16 and the establishment of the mode of inheritance (The French FMF Consortium 1997; The International FMF Consortium 1997), more than 120 mutations, most of which clustered in exon 10, have been identified in affected individuals (Touitou et al. 2004) . MEFV is predominantly expressed in granulocytes and monocytes activated by cytokines. MEFV expression is induced by pro-inflammatory agents such as interferon (IFN), tumor necrosis factor, and lipopolysaccharide γ, whereas the anti-inflammatory cytokines interleukin (IL) 4, IL-10, and transforming growth factor β inhibite such expression (Centola et al. 2000) . MEFV encodes pyrin which is a protein consisting of 781 amino acid residues. It has been revealed that pyrin plays an important role in innate immunity via regulating of IL-1β processing through binding apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), or even directly binding caspase-1 which activates IL-1β
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Colchicine is most effective drug that is used in treating or aborting the acute recurrent exacerbations of the disease and in preventing the development of amyloidosis (Majeed et al. 1990; Dewalle et al. 1998) . The aim of the current study was to determine the frequency of common MEFV gene mutations in patients with clinical and demographic manifestations of FMF in the population of Sivas, a city located in central Turkey.
Material and methods
In this study, 365 patients who applied us (Cumhuriyet University, Faculty of Medicine, Department of Medical Genetics) between December 2006 and January 2007 with FMF pre-diagnosis based on Tel-Hashomer criteria (Pras 1998; Samli et al. 2006) were included. Informed consent was obtained from all adults and parents of child cases.
A questionnaire including gender, age, use of colchicine, presence of fever, abdominal pain, arthritis, erysipelas-like erythema, amyloidosis, positive family history of FMF and appendectomy criteria was applied to all patients. Total genomic DNA was extracted from the 200 µL pheripheric blood samples by the Nucleospin blood (250) DNA isolation procedure (Macherey-Nagel, Germany). Certain regions encoding 12 common MEFV mutations (E148Q, P369S, F479L, M680I G/C, M680I G/A, I692del, M694V, M694I, K695R, V726A, A744S, R761H) were simultaneously in vitro amplified in biotin-labelled a single<multiplex>am-plification reaction (Vienna Lab, FMF StripAssay, GmbH, Austria).
PCR was performed in a Perkin Elmer 9600 and the profile consisted of an initial melting step of 2 min at 94 • C. The mutation analysis was performed by StripAssay technique (Vienna Lab, FMF StripAssay GmbH, Austria) which is based on the reverse-hybridization principle automatically. The normal, heterozygous and homozygous mutant/nonmutant genotype profiles of all alleles were determined using the enclosed Collector TM sheet for the FMF patients. Statistical analysis was performed using SPSS 14.0 program (SPSS Inc., Chicago, IL, USA). Data was compared using Chi-square test and Student's t-test as appropriate. P values less than 0.05 were considered as statistically significant.
Results
The cohort was composed of 365 patients (mean ages, for men: 22.1 ± 15.0 years and for women: 22.2 ± 14.1 years; range 2-87 yr), with a male:female ratio of 1:1.3. This difference was not statistically significant (p = 0.933). Ninety-nine percent of patients were living in the central part of Anatolia (Sivas/Turkey). Various combined and point mutations were detected in 270 (74%) patients that were investigated in the present study. No mutation was detected in the rest of other 95 (26%) patients. The genetic analysis of 270 mutation positive patients [(115 (42.6%) were women and 155 (57.4%) were men] revealed that M694V was (Table 1) . Carrier frequency has been estimated to reach 1:1.9 in this study. Allele frequencies of the patients who have mutation are shown in Figure 1 . The detected mutations (67.22% of the total 540 alleles) were mainly M694V, E148Q, M680I and V726A. The most common mutation in our FMF patients was the M694V heterozygote (26.85%) and followed by E148Q heterozygote (15.55%), whereas I694DEL and M680I (G/A) were not detected. The A744S, P369S, R761H mutations were found in 3.15%, 1.85%, and 1.11%, respectively. The F479I mutation was found in two patients. Mor et al (2005) . Comparison with Chi-square test between * and ** yields to p = 0.040 and between 1 and 2 (one and two mutated alleles, respectively) to p > 0.05.
In two complex alleles carried by two sisters it was found that P369S and E148Q mutations are resided on the same allele. Table 2 shows the frequency of genotypes in function of the clinical features in FMF patients. Especially, both M694V and E148Q mutations were found as most frequent in 46.5% of abdominal pain, in 39.1% of arthritis, in 36.2% of erythema, in 35.8% of fever and in 30.0% of amyloidosis. The phenotype severity was evaluated according to the subsequent genotype (Mor et al. 2005 ) in 268 patients (Table 2) . No differences were found when FMF patients carrying two mutated alleles (homozygotes or compound heterozygotes) were compared with those carrying only one mutated allele (heterozygotes); (p > 0.05). The M694V mutation, the M694V homozygotes, when compared with M694V compound heterozygotes, suffer from more severe disease (p = 0.040).
Phenotypic features according to the carrying one or two mutated alleles are presented in Figure 2 . There were statistically significant differences regarding the phenotypic features, such as fever (p = 0.004), arthritis (p = 0.015) and use of colchicines (p = 0.007), between patients carrying one or two mutated alleles.
Discussion
In the current study, the spectrum of MEFV gene mutations in relation with clinical features among FMF patients was studied. Our analysis clearly demonstrated that M694V mutation is characterized by high penetrance. However, the others are consistent with the diagnosis of FMF so as to their presence, even in heterozygosity. Most studies have reported that FMF affects both sexes in a similar ratio, although a male predominance was also suggested (Sohar et al. 1967) . Our results showed that the male/female ratio was 1:1.3, a similar ratio to that reported by Sayarlioglu et al. (2005) . It is known that abdominal pain attacks are the most common symptoms, occurring in about 75-95% patients. In our study, abdominal pain was observed in 170 (63.0%), patients. The frequency of abdominal pain among our FMF cases was similar to the result of other studies (Livneh et al. 1997; Dewalle et al. 1998 ). Appendectomy was found in 4.8% of our patients. Although we do not know exact postoperative diagnoses, we think that some of the patients that underwent appendectomy had been misdiagnosed as acute appendicitis before the diagnosis of FMF. Fever is a common feature of acute attacks, lasting 12 h to 3 days. Of our patients, 118 (43.7%) had fever accompanying acute attacks. Arthritis is more common in FMF patients than in the general population (Livneh et al. 1997; Dewalle et al. 1998 ). In our data, arthritis was detected in 102 (37.8%) patients. Erysipelas-like erythema is the only typical skin manifestation of FMF (Livneh et al. 1997) . It was reported in 7-40% patients with FMF (Dewalle et al. 1998) . It was found in 21.4% of our patients. Amyloidosis is the most significant complication of FMF, usually affecting the kidneys and resulting in renal insufficiency that progresses to end-stage renal disease. The frequency of amyloidosis differs among various ethnic groups and depends on whether patients are taking colchicines (Livneh et al. 1997; Dewalle et al. 1998) . Based on the previous reports, amyloidosis occurs in 20-60% of Turkish patients, in 27% of the non-Ashkenazi Jews and in only 1-2% of Armenians living in the United States (Ozer et al. 1971; Pras et al. 1982) . On the other hand, in two new studies from Turkey by Sayarlioglu et al. (2005) and by Ertekin et al.(2005) the frequencies of amyloidosis were found to be 5.5% and 4.8%, respectively. Amyloidosis was found in 3.7% of our patients. Relatively less frequency of amyloidosis in our study may be explained by earlier diagnosis, earlier onset of therapy and/or higher compliance to colchicine treatment. Our study confirms the mutational heterogenity of FMF in the Turkish population. Moreover, in a field study carried out in Sivas, a city located in central Turkey, Onen et al. (2004) indicated that the prevalence of FMF is higher than that in general Turkish population; with high compound heterozygosity (23.33%) confirming this suggestion. The carrier rate was 1:1.9, which is similar to previously reported carrier rates of FMF mutations in Armenians, Sephardic Jews, Arabic and Turkish population (Rogers et al. 1989; Yilmaz et al. 2001; Al-Alami et al. 2003) . Our data showed that the M694V mutation was the most common one (26.85%) of the tested alleles (Fig. 1) ; as it was already reported in other populations (Chen et al. 1998; Stoffman et al. 2000; Touitou 2001; Yilmaz et al. 2001 ). The E148Q mutation was the second most common one in our study group (15.55%), followed by M680I (9.62%), V726A (7.96%) and other mutations (Fig. 1) . In case of compound heterozygosity, the more severe clinical manifestations are expected as two mutations, which reside in different homolog chromosome, act like a homozygous mutation. In our study, fever (58.33%) and arthritis (50%) were detected to be significantly more frequent in patients bearing two mutations in different alleles compared to one mutation (p = 0.004 and p = 0.015, respectively).
Although a strong genotype-phenotype correlation is not documented in our study, the present data agree with the previously established knowledge that the presence of two mutated MEFV alleles lead to a more pronounced disease compared with single mutations and that M694V homozygosity correlates with the most severe FMF phenotypes (Table 2 ; Fig. 2 ) (Ben-Chetrit & Levy 1998; Touitou 2001; Zaks et al. 2003; Majeed et al. 2005; Medlej-Hashim et al. 2005; Sarkisian et al. 2005; Tunca et al. 2005) . Dewalle et al. (1998) also showed that, in patients who did not have regular colchicine therapy, the M694V homozygous genotype was associated with a more severe form of the disease (i.e. earlier age at onset, higher prevalence of pleurisy, higher frequency of arthritis, and a higher frequency of amyloidosis). Colchicine therapy was found in 14.8% of our patients. This condition may be explained by late diagnosis. The reverse hybridisation StripAssay is a reliable, time-saving technique for FMF diagnosis but failed to detect the small numbers of de novo sporadic mutated patients.
In conclusion, this study allowed the establishing the spectrum of the MEFV mutations among the FMF patients. The most important features were the predominance of the M694V and E148Q mutations. Previous results of presented study showed that patients having M694V/M694V carry a risk for amyloidosis.
